Monitor for the actual 510(k) submission and subsequent FDA clearance decision, which would be the material catalyst for U.S. market entry. No financial data to trade on from this filing alone.
Price Chart
Executive Summary
Intelligent Bio Solutions (INBS) announced completion of a usability study for its fingerprint-based drug screening system, supporting an FDA 510(k) submission for codeine detection. The study showed non-specialist operators could effectively use the system, but this is a routine regulatory milestone with no financial data or revenue impact disclosed. The company remains on track to submit the 510(k) package in H2 2026, targeting the U.S. market entry.
Key Facts
- Completed usability study for Intelligent Fingerprinting Drug Screening System, supporting FDA 510(k) submission for opiate codeine detection.
- Study conducted with 15 operators, confirming the system can be administered by operators with no specialist background.
- Company remains on track to submit 510(k) package in calendar H2 2026.
- No financial results, revenue, or guidance were disclosed in this filing.
Financial Impact
No financial data disclosed in this filing.
Risk Factors
- Regulatory risk: FDA 510(k) clearance is not guaranteed and could be delayed or denied.
- Commercial risk: Even with clearance, market adoption and revenue generation are uncertain for a $4M market cap company.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-036112 |
| Exhibit: ex99-1.htm | 0001493152-26-036112 |
| Document: 0001493152-26-036112-index-headers.html | 0001493152-26-036112 |
| Document: 0001493152-26-036112-index.html | 0001493152-26-036112 |
| Document: 0001493152-26-036112.txt | 0001493152-26-036112 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 10-K/A | $1.69 | awaiting T+20 | — | $1.64 (−2.67%) |
Oct 13, 2026 13d ago | 8-K | $1.45 | awaiting T+20 | — | $1.64 (+13.10%) |
Sep 24, 2026 4w ago | EFFECT | $1.71 $1.69 | ▲ +1.46% | ▲ +1.04% | $1.64 (+4.09%) |
Sep 15, 2026 5w ago | S-3 | $1.97 $1.48 | ▼ −24.87% | ▼ −28.05% | $1.64 (−16.75%) |
Sep 11, 2026 6w ago | 8-K | $2.07 $1.51 | ▼ −27.05% | ▼ −29.32% | $1.64 (−20.77%) |
Sep 9, 2026 6w ago | 8-K | $2.24 $1.59 | ▼ −29.02% | ▼ −30.96% | $1.64 (−26.79%) |
Sep 2, 2026 7w ago | 8-K | $2.30 $1.66 | ▲ +27.83% | ▲ +26.64% | $1.64 (+28.70%) |
Aug 19, 2026 9w ago | 8-K | $2.67 $2.05 | ▼ −23.22% | ▼ −21.70% | $1.64 (−38.58%) |
Aug 19, 2026 9w ago | Press Release | $2.67 $2.05 | ▲ +23.22% | ▲ +21.70% | $1.64 (+38.58%) |
Aug 17, 2026 10w ago | Press Release | $3.37 $2.05 | ▼ −39.17% | ▼ −37.19% | $1.64 (−51.34%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers